The Role of Olaratumab in Sarcoma

Results from the phase 3 COMMANDS study were presented in a press briefing ahead of the 2023 ASCO Annual Meeting.

In season 4, episode 5 of Targeted Talks, Alice P. Chen, MD, discusses important studies that are investigating treatment options for alveolar soft part sarcoma.

In the past 7 years, treatment for patients with non–small cell lung cancer has increased by over 100%, according to real-world data presented at iSPOR 2023.

In season 3, episode 2 of Targeted Talks, Mark Agulnik, MD, discusses molecular testing for patients with sarcoma, treatment with targeted therapies, and ongoing research.

Study findings presented at iSPOR 2023 reveal a substantial economic burden related to metastatic non–small cell lung cancer care, which impacts both patients and the healthcare system.

According to Alice P. Chen, MD, the phase 2 study of atezolizumab alone or atezolizumab plus bevacizumab has a unique design.